SCHEMBL469344

SCHEMBL469344

CC(C)[C@@H]1CC[C@@H](C)C[C@H]1NC(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 1.00
TRPV1 Q8NER1 9/20 0.73
MEN1 O00255 1/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
KMT2A Q03164 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
CNR2 P34972 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15103207 1.00 TRPM8 (1.00) TRPM8TRPV1MEN1NPC1RAB9A
SCHEMBL22289417 1.00 TRPM8 (1.00) TRPM8TRPV1MEN1NPC1RAB9A
SCHEMBL18552997 1.00 TRPM8 (1.00) TRPM8TRPV1MEN1NPC1RAB9A
SCHEMBL4081078 0.92 TRPM8 (0.85) TRPM8TRPV1
SCHEMBL4088459 0.92 TRPM8 (0.85) TRPM8TRPV1
SCHEMBL4083810 0.92 TRPM8 (0.85) TRPM8TRPV1
SCHEMBL4088451 0.83 TRPV1 (0.74) TRPM8TRPV1
SCHEMBL11886519 0.83 TRPV1 (0.74) TRPM8TRPV1
SCHEMBL11886340 0.83 TRPV1 (0.74) TRPM8TRPV1
SCHEMBL11886341 0.83 TRPV1 (0.74) TRPM8TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4268814-A2 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE Universidad Miguel Hernández De Elche (ES) 2023-11-01 EP claimed
EP-2614860-A2 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE Universidad Miguel Hernández De Elche (ES) 2013-07-17 EP claimed
EP-4268814-A2 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE Universidad Miguel Hernández De Elche (ES) 2023-11-01 EP disclosed
WO-2020160464-A1 TRANSIENT RECEPTOR POTENTIAL MELASTATIN 8 (TRPM8) ANTAGONISTS AND RELATED METHODS MARSHALL UNIVERSITY RESEARCH CORPORATION (US) 2020-08-06 WO disclosed
US-10028920-B2 Methods for treating occular irritation involving tearing by administering modulators of TRPM8 UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE (ES) 2018-07-24 US disclosed
US-10028920-B2 Methods for treating occular irritation involving tearing by administering modulators of TRPM8 UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE (ES) 2018-07-24 US disclosed
US-10028920-B2 Methods for treating occular irritation involving tearing by administering modulators of TRPM8 UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE (ES) 2018-07-24 US disclosed
US-9901549-B2 Method for treating vaginal dryness by administering transient receptor potential cation channel subfamily M member 8 (TRPM8) receptor agonists UNIVERSIDAD MIGUEL HERNÁNDEZ DE ELCHE (ES) 2018-02-27 US disclosed
US-9901549-B2 Method for treating vaginal dryness by administering transient receptor potential cation channel subfamily M member 8 (TRPM8) receptor agonists UNIVERSIDAD MIGUEL HERNÁNDEZ DE ELCHE (ES) 2018-02-27 US disclosed
US-9901549-B2 Method for treating vaginal dryness by administering transient receptor potential cation channel subfamily M member 8 (TRPM8) receptor agonists UNIVERSIDAD MIGUEL HERNÁNDEZ DE ELCHE (ES) 2018-02-27 US disclosed
US-20170071875-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS C.S.I.C. (ES) 2017-03-16 US disclosed
US-20150313854-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE (ES) 2015-11-05 US disclosed
US-9095609-B2 Ophthalmic composition comprising ws-12 and methods to treat xerophthalmia UNIVERSIDAD MIGUEL HERNÁNDEZ DE ELCHE (ES) 2015-08-04 US disclosed
US-9095609-B2 Ophthalmic composition comprising ws-12 and methods to treat xerophthalmia UNIVERSIDAD MIGUEL HERNÁNDEZ DE ELCHE (ES) 2015-08-04 US disclosed
US-9095609-B2 Ophthalmic composition comprising ws-12 and methods to treat xerophthalmia UNIVERSIDAD MIGUEL HERNÁNDEZ DE ELCHE (ES) 2015-08-04 US disclosed
US-20130245231-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS C.S.I.C. (ES) 2013-09-19 US disclosed
US-20130245231-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS C.S.I.C. (ES) 2013-09-19 US disclosed
US-20130245231-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS C.S.I.C. (ES) 2013-09-19 US disclosed
EP-2614860-A2 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE Universidad Miguel Hernández De Elche (ES) 2013-07-17 EP disclosed
WO-2012032209-A2 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE UNIVERSIDAD MIGUEL HERNÁNDEZ DE ELCHE (ES) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10028920-B2 Methods for treating occular irritation involving tearing by administering modulators of TRPM8 TRPM8, TRPM5, TRPM7 TRPM8 1/4885TRPV1 8/4885MEN1 1937/4885
US-20150313854-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE TRPM8, TRPM7, TRPM5 TRPM8 1/4885TRPV1 10/4885MEN1 2127/4885
US-20170071875-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE TRPM8, TRPM7, TRPM5 TRPM8 1/4885TRPV1 10/4885MEN1 2127/4885
US-20130245231-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE TRPM8, TRPM7, TRPM5 TRPM8 1/4885TRPV1 10/4885MEN1 2127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.